Malaria: Key Statistics, Biology, Drug Resistance, and Global Elimination Goals

Malaria remains a leading global health burden. 2022 WHO World Malaria Report estimates:

Epidemiology (2022)

• Cases: 249 million (85 countries).
• Deaths: 608,000.
• High burden: Africa 94% cases, 95% deaths. Nigeria (27%), DRC (12%), Uganda (5%), Mozambique (4%).
• Age: Children <5 = 76% of deaths.
• Species: P. falciparum dominant in Africa; P. vivax predominant in Americas, SE Asia, W. Pacific.

Transmission and Biology

• Vector: Female Anopheles (~40 vector species).
• Parasite complexity: 5,000+ genes; antigenic variation (var genes in falciparum) evades immunity.
• Relapse: P. vivax/ovale hypnozoites → dormant liver forms → reactivation.

Major Challenges

• Drug resistance: Artemisinin partial resistance (kelch13 mutations) in Greater Mekong, emerging in Africa. Partner drug resistance (piperaquine, mefloquine).
• Insecticide resistance: Pyrethroids (ITNs/IRS) — widespread. New nets: PBO, pyriproxyfen, chlorfenapyr.
• Vector behavior shifts: Outdoor/early biting, zoophily.
• Climate change: Altitude/latitude expansion, season extension.
• Conflict/displacement: Disrupts services, increases exposure.
• Funding gap: $3.8B available vs. $7.8B needed (2022).

Tools and Strategies

• Vaccines: RTS,S/AS01 (Mosquirix) — 36% efficacy over 4 yrs; R21/Matrix-M — 75% efficacy (phase 3). WHO prequalified both.
• New ACTs: Pyronaridine-artesunate, ganaplacide-lumefantrine.
• Monoclonal antibodies: CIS43LS (L9LS) — seasonal protection trial.
• Gene drive / Wolbachia: Vector suppression/replacement — field trials.
• Surveillance: Genomic (resistance tracking), digital (case reporting).

Global Targets (WHO Global Technical Strategy 2016–2030)

• Reduce incidence and mortality ≥90% by 2030.
• Eliminate in ≥35 countries.
• Prevent re-establishment in malaria-free countries.

Progress stalled since 2015. Renewed investment, innovation, and equity-focused delivery are essential to bend the curve.